PC22039A Information Disclosure Statement For Appln. No. 10/601,355



<u>Certificate of Mailing (37 C.F.R. §1.8):</u>
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Commissioner for Patents,

PO Box 1450, Alexandria, VA 22313-1450

on this 29th day of August 2003.

Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Anthony David Auffret et. al.

Serial No.: 10/601,355

Filed: June 23, 2003

For: PROCESS FOR CONTROLLING THE

HYDRATE MIX OF A COMPOUND

Group Art Unit: To be Announced

Examiner: To be Announced

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form to Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified at 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: August 29, 2003

Elsa Djuardi

Attorney For Applicants Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 638-6117

Fax: (858) 678-8233

U.S. Patent and Trademark Office; U.S. Department of Commerce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

| ubstitute for form 1449/PTO | Compl te if Known | | |
|---|------------------------|------------------------|--|
| | Application Number | 10/601355 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Us as many sh ts as necessary) | Filing Date | June 23, 2003 | |
| | First Named Inventor | Auffret, Anthony David | |
| | Art Unit | To be Announced | |
| | Examiner Name | To be Announced | |
| | Attorney Docket Number | PC22039 | |

| NEW B JUNE | U.S. PATENT DOCUMENTS | | | | |
|---------------------|-----------------------|-------------------------------|--------------------------------|--|--|
| EXAMINER INITIAL | Cite No. 1 | DOCUMENT NUMBER | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|---------------|---|-----------------------------|---|---|----------|
| EXAMINER INITIAL | Cite No. 1 | Foreign Patent Document Country Code3 Number4 Kind Code5 (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T° |
| | Α | WO 97/28169 | 08-07-1997 | Murtiashaw, Martha H. | | |
| | | | | | | <u> </u> |
| | | | | | | |
| | | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---|--|--|--|--|
| Examiner Initials Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or coun where published. | | | | |
| | | | | |
| | | | | |
| | | | | |

| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|
| | |

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.